Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies [0.03%]
用理性联合用药策略克服B-ALL对靶向和免疫治疗的耐药性
Miguel Quijada-Álamo,Grace Freed,Elvin Wagenblast
Miguel Quijada-Álamo
Despite the remarkable efficacy of targeted therapies and immunotherapies in B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory cases remain a major challenge. In this review, we discuss how integrating targeted agents wit...
One for All and All for One: New Insights into Enhancers Driving MYC Dysregulation [0.03%]
共治失调：调控MYC异常表达的增强子的新见解
Roger Mulet-Lazaro,Ruud Delwel
Roger Mulet-Lazaro
The role of the proto-oncogene MYC as a driver of lymphoma has been known since the 1980s, but the mechanisms underlying its dysregulation are not completely understood. In this issue of Blood Cancer Discovery, Iyer and colleagues employ a ...
The Paradox of Acute Myeloid Leukemia Responsiveness to Adoptive T-cell Therapy [0.03%]
急性髓系白血病对过继性T细胞治疗反应性的悖论
Terry J Fry
Terry J Fry
Since the recognition of the allogeneic graft-versus-leukemia effect, acute myeloid leukemia (AML) has been identified as a T cell-targetable malignancy, but success with modern forms of immunotherapy has been slower than anticipated. In th...
Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma [0.03%]
克隆演变与多发性骨髓瘤临床结果无关
Camila Guerrero,Maria-Jose Larrayoz,Irache Erdozain et al.
Camila Guerrero et al.
SPMs that develop in patients with multiple myeloma have a deleterious impact on survival. Patients with CH may be at risk of developing SPMs, which could potentially be avoided through individualized treatment. However, our results suggest...
Beyond Trial and Error: A Mathematical Model Wrangles DLBCL Heterogeneity Toward Optimizing Combination Therapy [0.03%]
超越试错：一个数学模型通过优化联合治疗来应对DLBCL的异质性
Jordan S Goldstein,Nick A Phillips,Ash A Alizadeh
Jordan S Goldstein
In this issue of Blood Cancer Discovery, Pomeroy and Palmer present a new mathematical model, incorporating both inter- and intra-patient heterogeneity, to accurately predict outcomes for first-line combination therapies in diffuse large B-...
Nguyen Huong Jenny Giang Ho,Nana Talvard-Balland,Natalie Köhler et al.
Nguyen Huong Jenny Giang Ho et al.
We discuss the mechanisms of AML immune evasion including loss or downregulation of MHC class I and II, reduced TRAIL receptor expression, inhibitory metabolite production, inhibitory ligand expression, impaired proinflammatory cytokine pro...
Enhancer hijacking discovery in acute myeloid leukemia by pyjacker identifies MNX1 activation via deletion 7q [0.03%]
急性髓性白血病中通过pyjacker发现的增强子劫持识别出7号染色体缺失导致的MNX1激活
Etienne Sollier,Anna Riedel,Umut H Toprak et al.
Etienne Sollier et al.
Acute myeloid leukemia with complex karyotype (ckAML) is characterized by high genomic complexity, including frequent TP53 mutations and chromothripsis. Genomic rearrangements that reposition active enhancers near proto-oncogenes, leading t...
Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges [0.03%]
人工智能推动CAR T细胞疗法的发展：机遇与挑战
Fabio Luciani,Arman Safavi,Puneeth Guruprasad et al.
Fabio Luciani et al.
Artificial intelligence could enhance chimeric antigen receptor T-cell therapy outcomes through optimization of all steps, from target identification, vector design, and manufacturing to personalized data-driven clinical decisions. In this ...
Victoria da Silva-Diz,Daniel Herranz
Victoria da Silva-Diz
Drugs targeting metabolism have been effectively used in patients with T-cell acute lymphoblastic leukemia (T-ALL) for decades; still, the full therapeutic potential of targeting metabolism has not been completely exploited yet. Here, we hi...